InvestorsHub Logo
Followers 58
Posts 5142
Boards Moderated 0
Alias Born 07/23/2007

Re: None

Thursday, 08/28/2014 12:53:46 PM

Thursday, August 28, 2014 12:53:46 PM

Post# of 1121
TRIFECTA trial question, just wondering, open to opinions on this:

Upon reaching the number of targeted patients, a second blinded interim analysis indicated a significant clinical signal without any safety concerns.

Given the stopping threshold had been met, the data review committee said there was sufficient evidence of a treatment effect to warrant ending the study.

Then how can the top-line results--scheduled for release in Sepember-- be anything but positive?

All that is needed to make a happy life is within yourself, in your way of thinking. -Marcus Aurelius

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ACST News